Mechanism of action

Semaglutide is a selective GLP-1 receptor agonist. Long-acting analog with side-chain modifications extending half-life to ~7 days. Tirzepatide is the first dual GIP/GLP-1 agonist — a single peptide activating both incretin receptors. The GIP component amplifies the weight-reducing effect through complementary mechanisms in adipose tissue and hypothalamic signaling.

SURPASS-2 head-to-head trial

SURPASS-2 (Frias JP et al., NEJM 2021, PMID 34170647) compared tirzepatide and semaglutide 1 mg in 1,879 adults with T2D over 40 weeks:

ArmHbA1c reductionWeight change
Tirzepatide 5 mg-2.01%-7.6 kg
Tirzepatide 10 mg-2.24%-9.3 kg
Tirzepatide 15 mg-2.30%-11.2 kg
Semaglutide 1 mg-1.86%-5.7 kg

Note: SURPASS-2 used semaglutide 1 mg (T2D dose), not 2.4 mg (obesity dose). Comparing tirz 15 mg in obesity to sema 2.4 mg in obesity (separate trials) narrows the gap.

Obesity trial results

In separate dedicated obesity populations:

Drug · TrialMean WL at 68-72wk≥10% WL
Semaglutide · STEP-1 (n=1,961)-14.9%69.1%
Tirzepatide · SURMOUNT-1 (n=2,539, 15 mg)-20.9%90.0%

Cardiovascular outcomes

Semaglutide: SELECT (Lincoff AM et al., NEJM 2023, PMID 37952131) showed 20% MACE reduction in 17,604 adults with BMI ≥27 + established CVD. Led to Wegovy CV indication (March 2024).

Tirzepatide: No published CV outcome trial as of May 2026. SURPASS-CVOT enrolling, readout 2027.

For patients with established CVD, semaglutide has the relevant evidence base today.

FDA-approved indications

IndicationSemaglutideTirzepatide
T2DOzempic (2017), Rybelsus oral (2019)Mounjaro (2022)
Chronic weight managementWegovy (2021)Zepbound (2023)
CV risk reduction (obesity + CVD)Wegovy (Mar 2024)Not yet
OSA in obesityNot approvedZepbound (Dec 2024)

Compounded pricing (May 2026)

ProviderSema (12-mo plan)Tirz (12-mo plan)
NexLife$145/mo flat through 2.4 mg$186/mo flat through 15 mg
Mochi Health~$178/mo~$208/mo
Henry Meds~$279/mo~$369-449/mo
Eden Health~$189-249/mo~$229-349/mo

How to choose